Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Mingyang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4101-716X; OpenAlex author ID A5100443443. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 2 papers · 2024: 1 paper

Papers 16

  1. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Co-author DOI 10.1016/j.ccell.2024.03.009↗
  2. ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experimental analysis. Co-author DOI 10.1007/s10142-023-01122-z↗
  3. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular. Co-author DOI 10.1016/j.canlet.2023.216391↗
  4. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  5. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.02.017↗
  6. Arid1a: A Gatekeeper in the Development of Pancreatic Cancer From a Rare Precursor Lesion. Co-author DOI 10.1053/j.gastro.2022.05.046↗
  7. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.06.058↗
  8. Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-022-01585-x↗
  9. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103271↗
  10. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.12.077↗
  11. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01153-1↗
  12. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  13. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis. Co-author DOI 10.1158/1078-0432.ccr-18-4113↗
  14. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Co-author DOI 10.1158/1078-0432.ccr-18-0263↗
  15. Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. Co-author DOI 10.1158/1078-0432.ccr-18-1126↗
  16. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-015-3690-x↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jingxuan Yang · 10 shared papers, 2018–2024 · strength 1.10
  2. Min Li · 7 shared papers, 2019–2024 · strength 0.88
  3. Zhijun Zhou · 7 shared papers, 2018–2024 · strength 0.86
  4. Xiuhui Shi · 6 shared papers, 2021–2024 · strength 0.80
  5. Courtney W. Houchen · 6 shared papers, 2018–2024 · strength 0.74
  6. Xiaohao Zheng · 1 shared paper, 2023 · strength 0.26
  7. Chengfeng Wang · 1 shared paper, 2023 · strength 0.26
  8. Yongxing Du · 1 shared paper, 2023 · strength 0.26
  9. Xiaofan Ren · 2 shared papers, 2020–2022 · strength 0.25
  10. Zhiqiang Fu · 2 shared papers, 2020–2022 · strength 0.25
  11. Huilin Ye · 2 shared papers, 2020–2022 · strength 0.25
  12. Changhao Chen · 2 shared papers, 2020–2022 · strength 0.25
  13. Yuming Luo · 2 shared papers, 2020–2022 · strength 0.25
  14. Shangyou Zheng · 2 shared papers, 2020–2022 · strength 0.25
  15. Lei Zheng · 2 shared papers, 2018–2024 · strength 0.23
  16. Hanxiang Zhan · 2 shared papers, 2021 · strength 0.22
  17. Ou Li · 1 shared paper, 2023 · strength 0.19
  18. Li Li · 1 shared paper, 2023 · strength 0.19
  19. Weiwei Jin · 1 shared paper, 2023 · strength 0.19
  20. Yiping Mou · 1 shared paper, 2023 · strength 0.19
  21. Alex Arreola · 1 shared paper, 2024 · strength 0.17
  22. Ryan David Nipp · 1 shared paper, 2024 · strength 0.17
  23. Rufu Chen · 1 shared paper, 2022 · strength 0.15
  24. Min Li · 2 shared papers, 2018–2019 · strength 0.12
  25. Yuqing Zhang · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.